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r e s o u r c e both will compete for free CYP enzyme ( Supplementary Fig. 2) . The qHTS data for each of the five CYPs are shown in Figure 1a and are available in PubChem.
Analysis and comparison of CYP activity
A high degree of inhibitory activity for all five isozymes was observed in the 17,000-compound collection (30-78% of the collection inhibited any one CYP isozyme). High-confidence activating CRCs (compounds that increased the rate of proluciferin conversion) were only appreciably observed in CYP 3A4 (2.5%) and CYP 2C9/2C19 (~3.5% each). Activation of CYP isozyme activity is typically substrate dependent 17, 18 , so the present assays would not be expected to comprehensively characterize this type of behavior.
By examining the distribution of half-maximal inhibitory concentration (IC 50 ) within high-and low-confidence inhibitory compounds ( Fig. 1b) , we observed that compounds in the biofocused and MLSMR libraries were selective for specific CYP isozymes. For example, both libraries showed a similar frequency of activity towards CYP 2D6, whereas the biofocused library was considerably less active against CYP 2C9 and 2C19 ( Fig. 1b) and to a lesser extent against 1A2 and 3A4. When the distribution of potency between the MLSMR and FDA-approved drugs was compared, we found few significant isozyme-specific differences except for CYP 1A2, where the FDA drugs appeared to be less potent than the MLSMR, and CYP 2D6, where the FDA drugs were more potent than the MLSMR (P < 0.01; Supplementary Fig. 3) . We observed additional differences between the biofocused, MLSMR and combinatorial chemistry compounds in both the number and distribution of inhibitory CRCs across the five CYP isozymes. In the MLSMR an average of 58 ± 16% of compounds were found to be active against any specific isozyme. The biofocused library showed approximately half this activity (average of 32 ± 8%). FDA drugs (18% of the biofocused library) showed similar activity (average of 31 ± 8%). In contrast, the combinatorial library showed an average activity (52 ± 19%) similar to that of the MLSMR subset. CYP 1A2 and CYP 3A4 showed strong activity for a specific class of quinazoline compounds (60-75% of this compound class was active), which is a common scaffold found among protein kinase inhibitors.
The importance of FDA-approved drugs, and the large difference in activity between these and the MLSMR, prompted us to further compare the CYP activity between the two collections. As shown in Figure 2a , 33 .3% of FDA-approved drugs were inactive against all five isozymes compared to 7.1% of compounds from the MLSMR subset. Pan-activity (e.g., inhibition against all five isozymes) was increased approximately twofold in the MLSMR subset compared to the FDA drugs (8.0% and 3.8%, respectively). Also, there was a steady decline in the percentage of active compounds when more than one CYP was active in the FDA-approved drugs ( Fig. 2a) . FDA drugs were less active, both in terms of the percentage of compounds interacting with any isozyme combination, and the average number of isozymes interacting with each compound. Therefore, historically, drugs have been optimized to have low combination CYP activity, with fewer drugs showing activity against more than three CYPs.
The two CYP 2C isozymes (CYP 2C9 and 2C19) were the least affected by the FDA drugs compared to MLSMR compounds (46% and 57% fewer compounds in the FDA drugs, respectively; r e s o u r c e Fig. 2b ). Both CYP 3A4 and 1A2 were differentially affected to a lesser degree (~24% difference for each), and CYP 2D6 showed a 5% difference between the two libraries. We also found that when only one isozyme was active this was unlikely to be either CYP 2C19 or 2C9 for the MLSMR (Supplementary Fig. 4 ). Therefore, although hepatic CYP activity and distribution ( Fig. 2b ) emphasizes the role of CYP 3A4 in drug metabolism, drugs appear to have been optimized to have low CYP 2C9 and 2C19 inhibitory activity.
Identification of active chemical series
To assess whether structurally similar compounds affected specific CYP isozymes, we clustered all 17,000 compounds based on their structural similarity and represented these as self-organizing maps (SOMs; Fig. 3 ) 19, 20 . In the SOMs, each hexagon represents a cluster of structurally similar compounds, with neighboring hexagons containing more similar structures than distal hexagons. This approach identified a quinazoline class of compounds that affected CYP 1A2 but not the other four isozymes ( Fig. 3 , hexagons along the lower edge that are red in the CYP 1A2 SOM and blue in others). We also found structures that affected combinations of isozymes: two hexagons in the bottom left corner in the SOMs represent structures that are active (red) against CYP 2C19, 2C9 and 3A4 but inactive (blue) against CYP 1A2 and 2D6. The number of compounds active against all isozymes is relatively small (n = 350), and all share a relatively high degree of structural similarity, reflected in the few hexagons that are clustered together and colored red in all five SOMs. Conversely, the number of pan-inactive compounds is quite large (n > 2,000, blue cluster of hexagons in all five SOMs).
Once the activity data were organized by SOMs, we could relate the activity patterns to the genetic sequence similarity of the human CYP isozymes. We hierarchically clustered (using a Minkowski distance as the similarity metric) the five isozymes using the compound activity patterns, and the resulting dendrogram is shown in Figure 3 . Clustering divided the five isozymes into two major groups, one consisted of CYP 2C19, 2C9 and 3A4, with CYP 2C9 and 2C19, which are the most similar in sequence, having the most similar activity patterns, and the other one consisted of CYP 1A2 and 2D6, although these latter two showed a lesser degree of activity similarity.
Identification of activity-differentiating substructures
To identify structural features that differentiate between active and inactive compounds, we searched for substructures disproportionately represented in particular CRC classes relative to the entire testing set (16, 144 unique compounds from the 17,000-compound library; see Online Methods). A selection of the results for structural features that differentiated between active and inactive compounds or showed isoform specific behavior is given in Figure 4 (additional substructures are in Supplementary Table 1 ). To obtain the most accurate associations, we focused on the high-confidence inhibitory CRC classes and the inactive class. Activating CRC categories are not shown because of the relative dearth of records in this class.
A number of chemical substructures were associated with inhibitory and inactive compounds ( Fig. 4) . The presence of an aliphatic alcohol group (1) was associated with compounds inactive against four of the five isozymes. The presence of an aromatic hydroxyl group was associated with a similar but weaker trend, as was the presence of an ether linkage (data not shown). The presence of a primary aliphatic amine (2) or a quaternary ammonium salt (5) was also associated with compounds showing pan-isoform inactivity. In contrast, secondary and tertiary aliphatic amines (3 and 4, respectively) were associated with isoform-specific behavior, associated with the inhibitor and/or substrate response class for CYP 2D6 but with the inactive class for other isozymes. This is consistent with the known preference of CYP 2D6 for substrates containing basic, protonatable nitrogen atoms 21 . Coloring is scaled by the negative log 10 of the P-values (not corrected for multiple hypothesis testing). The group of blue hexagons that consistently appear in the top middle region of the SOMs represent structurally related compounds that tend to be inactive against all five CYP isozymes. Isozyme SOMs are ordered left to right according to hierarchical clustering using Minkowski distance.
r e s o u r c e
The presence of a carboxylic acid moiety (6) was also strongly correlated with pan-inactivating compounds. This can be compared with the trends for simple esters, amides and carbamates, which are generally much weaker and less consistent (data not shown). Imide (7) and urea (8) functionalities showed similar patterns to carboxylic acids, although with weaker associations. In the case of imides, the combinatorial library that contained a high density of this functionality ( Fig. 5 ) may explain the weaker association. Oxime o-ethers (9), sulfonates (10) and phosphorus groups (11) were additional moieties associated with inactive compounds, although the frequency of occurrence of the latter in the testing set was low.
In terms of simple rings, the presence of oxolanes (12) was correlated with pan-inactive compounds. Aromatic equivalents such as thiophenes (13) , furans and pyrroles (data not shown for the latter two) were associated with pan-activating compounds. Other aromatic groups such as pyrimidines, indoles, benzodioxoles and naphthalenes (14 to 17) were also generally associated with inhibitor/substrate compounds, particularly for CYP 1A2 (known to have preference for planar, polyaromatic substrates) 6 .
To identify more complicated substructures, we performed a similar analysis to that previously outlined 10 . For each isoform, inactive, highconfidence inhibitory and high-confidence activating compounds were clustered using extended-connectivity fingerprints (Pipeline Pilot 6.1, Scitegic, 2006, http://accelrys.com/products/scitegic). For each cluster the maximal common substructure was identified, which was then used to search the whole test set for similar structures. This process was repeated several times with slightly different parameters for each isoform, in an attempt to ensure that a representative sample was taken.
The most prominent substructures from this analysis are summarized in Figure 5 . We identified additional substructures associated with pan-inactive compounds, including long aliphatic carbon paths (18) . Substructures incorporating simple chemical functionalities such as (19, 22) showed isoform-specific behavior. Purine scaffold (20) and steroidal (24) compounds appeared to be largely inactive, consistent with the role of CYPs as largely metabolic rather than biosynthetic enzymes 8 . In contrast, a monosaccharide substructure (23) was associated with isoform-specific behavior-inactivity against CYP 1A2 but activity against CYP 3A4. We found that 89% of the compounds containing the quinazoline structure (19) were assigned to highconfidence inhibitory CRCs for CYP 1A2, compared with only 8% for CYP 2C9. The known preferences of the CYP 1A and CYP 2C family of isozymes for planar, polyaromatic and nonplanar substrates, respectively 6 , explain this observation.
Scaffolds 21 and 22 were contained in two combinatorial libraries that were included in the testing set and shown in more detail in Supplementary Figure 5 . The analysis method used here often required visual inspection to judge whether an identified substructure truly constituted an important common element. For example, the automated maximal common substructure procedure (and indeed the chemical group analysis) highlighted parts of the scaffolds shown in Supplementary Figure 5 , but without visual inspection we would not have identified the corresponding combinatorial libraries. r e s o u r c e DISCUSSION Using qHTS, we have defined pharmacological profiles of CYP activity with respect to libraries that included drugs, unoptimized commercially available compounds and combinatorial collections. A key advantage of this database is that the data are from a single series of experiments that used a bioluminescent assay format to determine potency for every compound. This allowed CRCs to be categorized to define activity and to directly compare results between isozymes. The CYP gene family has evolved to cover a wide range of chemical structures. We found that at least one isozyme was active in 93% of the MLSMR and 72% of the biofocused compounds. The database should aid in constructing and testing new predictive models of CYP activity. We recognize that comparison of trends between isozymes provided here must be treated with care, as different probe substrates were used for the various isozymes (although all were based on luciferin), and this has previously been shown to influence observed effects on CYP activity [22] [23] [24] . Overall, the bioluminescent assays demonstrated a correlation similar to that of CYP fluorescent assays when compared to conventional methods such as analytical detection of products (Online Methods). Excellent correlations were observed for CYP 1A2, 2C9 and 2D6 (r 2 values of 0.91, 0.84 and 0.94, respectively). CYP 2C19 and 3A4 also performed well, but were less well correlated (r 2 values of 0.54 and 0.74, respectively; Supplementary Fig. 6 ). Inhibitory activity in the assay may be due either to compounds acting as substrates or inhibitors, and some weak-binding substrates may be classified as 'inactive' (highest testing concentration was 57 µM). As our assay protocol did not include preincubation of compound with CYP, this database will be less sensitive toward time-dependent inhibitors and will miss mechanism-based inhibitors.
To assess if the potencies observed are clinically significant, we compared the IC 50 to the C max value (maximum plasma concentration of the drug) for ~140 drugs that inhibited one or more of the CYPs. From this analysis and based on FDA guidelines, we estimate that drug-drug interactions are probable for ~20% of the study drugs showing inhibition, although the FDA criteria (drug-drug interactions are probable with [I]/K I > 0.1) is stricter than what is typically applied in early optimization efforts (Supplementary Fig. 7) .
Two isozymes, CYP 2C9 and 2C19, showed selectivity between drugs and the MLSMR. It has been suggested that CYP 3A4 is the most prominent P450 isozyme in drug metabolism and hepatic distribution (Fig. 2b) 25, 26 , but the drugs in our collection do not appear to have been optimized away from this activity. There has also been speculation that CYP 2D6 isozyme plays a prominent role in drug metabolism 27 , but we did not observe differences in activity between MLSMR compounds and FDA-approved drugs for this isozyme. Our data show drugs to be more potent against CYP 2D6 than against the unoptimized compounds from the MLSMR, indicating that CYP 2D6 activity has not been an historical consideration in drug optimization efforts. Taken together, the CYP 2C family shows similar involvement in drug metabolism as CYP 3A4 (ref. 28 ), and CYP 2C9 shows a hepatic expression level similar to that of CYP 3A4 (Fig. 2b) . Therefore, although activity against any or all CYP isozymes should be considered during lead optimization, the analysis provided here suggests that, historically, drugs have been particularly optimized against CYP 2C9 and 2C19 isozymes and that consideration of CYP 2C family activity should be particularly informative in drug optimization efforts.
Comparison of bulk compound properties between active and inactive compounds showed a slight differential for parameters related to aqueous solubility (Supplementary Fig. 8) , consistent with trends shown in Figures 4 and 5 such as the prevalence of aliphatic alcohol or charged groups among pan-inactives compounds. However, analysis of compound fragments also showed isozyme-selective substructures. Biochemicals such as steroids and purines were among the less active fragments, consistent with these five isozymes being primarily involved with xenobiotic metabolism. Common ring systems were more heterogeneous in their effects on CYP isozymes, with oxolanes showing a preference for pan-inactivity, whereas similar rings such as thiophenes or furans correlating with pan-activity.
Many computational strategies have been advanced to generate predictive CYP isozyme activity models [29] [30] [31] [32] [33] . Several factors have been implicated in their limitations; foremost among these is the lack of a single large, diverse data set of CYP isozyme activities 34 . We expect that the data set described here will facilitate the development of more-robust CYP activity models. AID: 1379; only 0.7% were found to be interfering in the compound collection described here). We also examined whether nonspecific inhibition due to compounds that form aggregates 37 occurred to a high degree in the CYP assays, a phenomenon that may be particularly relevant to the compounds that appear as activators of enzyme activity 38 . However, we noted that CYP 3A4 activators didn't appear to be more or less selective or promiscuous than other compounds in our collection against multiple assays (data not shown). Also in line with this observation is that the activators observed for one CYP did not overlap with other CYPs supporting specific enzyme activation as opposed to a general nonspecific effect such as aggregation. CYP enzymes are already packaged in membrane structures, which may help to mitigate aggregation-based nonspecific inhibition. For this reason, testing for detergent sensitivity could not be used as a counter-screen for colloidal aggregates due to greatly reduced activity of the CYP microsome preparations in the presence of detergent (both 0.1% and 0.01% TWEEN-20 and Triton were tried leading to a loss of luminescent signal).
METHODS

Methods and any associated references are available in the online version
As an alternative to detergents, to assess the effects of aggregation, we screened 44 randomly selected compounds against higher concentrations of CYP 3A4 and 2C9 (ref 39 ). Thirty-one compounds showed inhibition against CYP 3A4, and 29 showed inhibition against CYP 2C9. Compounds were titrated as 24-point twofold dilution series. We measured potencies in the bioluminescent assays under normal and high concentrations (100 nM, corresponding to 5× and normal assay enzyme concentration for CYP 3A4 and 10× for CYP 2C9). Linear conditions were maintained, and we then compared the IC 50 s and Hill slopes of each compound at the two enzyme concentrations.
We observed an average shift of approximately two-to threefold (range 0.7to fourfold; MSR for CYP 3A4 and 2C9 were 1.8 and 3.6, respectively). Only one compound showed a shift of fourfold in CYP 3A4 with two compounds showing a shift ~4.5-fold in CYP 2C9. The average Hill coefficient was not greatly affected by the two conditions (values of 1.5/1.2 at normal enzyme concentration and 1.6/1.4 at high enzyme concentration, CYP 3A4/CYP 2C9, respectively). Therefore, irrelevant inhibitory effects due to compounds forming aggregates, which may bind and inhibit the enzyme with high affinity, do not appear to affect the CYP assays as conducted in this study, even though detergent was not present in the assay.
Testing of inhibitors and substrates. We examined several known substrates of CYP isozymes to determine the effect that these compounds have on proluciferin conversion (Supplementary Fig. 2) . Phenacetin is the FDA-preferred substrate 40, 41 for in vitro CYP 1A2 studies, and theophylline and tacrine are acceptable FDA substrates for in vitro CYP 1A2 studies. Substrates such as phenacetin demonstrated AC 50 s (that is, compound concentration that leads to 50% of the activity of an inhibition or activation control) that were within the range of reported K M s (e.g., AC 50 = 2.5 µM, range 1.7-152 µM; Supplementary  Fig. 2) . However, the highest tested concentration in the present assay was 57 µM and substrates with weaker K M s showed only weak activity or were inactive in the assay, as in the example of theophylline (reported K M values between 10 and 1,000 µM; Supplementary Fig. 2 ).
Statistical assessment of qHTS CYP assay performance.
A mean Z′-factor 42 of 0.60 was determined for the biofocused library (Z′-factors for 1A2 = 0.69, 2C9 = 0.67, 2C19 = 0.35, 2D6 = 0.55, 3A4 = 0.72) whereas the MLSMR subset had a mean Z′-factor of 0.56 (Z′-factors for 1A2 = 0.74, 2C9 = 0.60, 2C19 = 0.16, 2D6 = 0.71, 3A4 = 0.60). For CRC-based screening the reproducibility of the AC 50 s is the most relevant measure of data quality 43 . For the present data set we calculated the minimum significant ratio (MSR) 44 for the control inhibitor titrations for all five isozymes. We found a mean MSR of 5.5 ± 4.4 with a mean s.d. of 0.23 ± 0.11 log AC 50 units (calculated using concentration of mol/l) in the biofocused collection and a mean MSR = 1.8 ± 0.4 with a mean s.d. of 0.08 ± 0.03 log AC 50 units for the MLSMR subset. To further validate the assays we obtained 91 randomly selected compounds for which bioassay data from another laboratory had also been published in PubChem (AIDs: 1024, 1025) and retested these in the CYP assays. A sample was considered 'confirmed' if it was found as active or inactive in both the original qHTS and confirmation experiments. We observed excellent confirmation (mean 86% ± 2; ranging between 84-90%) for all five isozymes (Supplementary Fig. 1) .
ONLINE METHODS
Reagents.
Luciferase-based P450-Glo Screening Systems were obtained from Promega for CYP 1A2 (V9770), CYP 2C9 (V9790), CYP 2C19 (V9880), CYP 2D6 (V9890) and CYP 3A4 Luciferin-PPXE (V9910) and were adapted for 1,536-well microplates and an automated protocol. Recombinant P450 enzymes were obtained from baculovirus constructs expressed in insect cells (BD/Gentest). The control compounds furafylline for 1A2, sulfaphenazole for CYP 2C9, ketoconazole for CYP 2C19, quinidine for 2D6, and ketoconazole for 3A4 were purchased from Sigma Aldrich. The 1,536-well microplates that were specifically bar coded for the Kalypsys automated robotic system were purchased from Greiner Bio-One.
Compound library and preparation of control plates. The 6,144 member biofocused library was collected from several sources and the composition of the compounds tested in this analysis were as follows: 31% National Cancer Institute, 18% LOPAC (Sigma Aldrich), 13% TOCRIS (TOCRIS), 18% Prestwick (Prestwick Chemical), 20% CMLD (Centers for Chemical Methodology and Library Development; 12% Boston University and 8% University of Pennsylvania). The biodiverse compound library consisted of 8,448 compounds (8,018 compounds are reported here) randomly selected from the larger 60,000 NIH MLSMR. Briefly, 10 mM stocks of compounds were diluted 7 times in a fivefold manner using an interplate dilution protocol; detailed library preparation is described elsewhere 35 . Controls were added from a separate 1,536-well compound plate as follows: columns 1 and 2, 16-point titrations in duplicate of the appropriate inhibitor (both beginning at 10 mM in DMSO for all isozymes except CYP 2D6, for which the starting concentration was 250 µM); column 3, the neutral control (DMSO); column 4, the appropriate control inhibitor (present at either 57 µM or 1.4 µM for CYP 2D6).
qHTS of CYP isozymes. The qHTS assay was performed in 1,536-well plates using an assay volume of 4 µl, with a throughput of ~7 samples/second. White 1,536-well solid bottom plates were incubated at the appropriate temperature (room temperature, ~25 °C for CYP 1A2, 2D6 and 3A4 and at 37 °C for CYP 2C9 and 2C19). The Kalypsys dispenser was used to dispense 2 µl enzyme and substrate mix. Then, control and compound collections were added with a Kalypsys pin tool through transfer of 23 nl of compound solution in DMSO. The plates were then incubated for 10 min at their respective incubation temperatures. The reaction was initiated through the addition of 2 µl NADPH regeneration solution with the Kalypsys dispenser. The reaction was allowed to continue for 1 h before it was stopped with a detection reagent that contained luciferase and ATP to generate a luminescent signal. The plate was incubated for another 20 min before being read on a Viewlux (Perkin Elmer) with 2× binning and an exposure of 60 s. The final 1,536-well assay protocol is summarized in Supplementary Table 2 .
Classifying CRCs as inhibitory, activating or inactive. A total of 17,143 compounds had nonequivocal CRCs against all five isozymes, though more compounds were tested for each isozyme. Compounds with unavailable/equivocal data for even one CYP were not considered for analysis. This was done to have homogeneous data across the isozymes to facilitate comparisons between them. In-house software was used to classify the titration response by assigning curve classes based on shape, potency and fit of curve to the data. Class 1 constitutes a CRC that has lower and upper asymptote; class 2 has only an upper asymptote; class 3 shows activity only at highest concentration tested; class 4 shows no activity. As an additional criteria of activity we placed the CRCs into high-confidence (category 1) and low-confidence (category 2) CRCs based on the quality of the fit to the data 10, 36 . The category 1 CRC showed classes 1 or 2 CRCs with an efficacy of ≥60% inhibition. Any other activity was considered to have lower confidence and placed in category 2. Similarly, categories 3 and 4 designated high-and low-confidence activating CRCs.
Controlling for assay artifacts and aggregation-induced nonspecific inhibition.
To address potential artifacts due to the assay format, particularly important for pan-active compounds, we used a database of potency values determined for the variant of the firefly luciferase used in the assay to remove any compounds that interfered with luciferase detection 12 (PubChem Follow-up analysis. Follow-up compounds were ordered and prepared as 24-point titrations using a serial dilution (1:1) within the same plate. Plates were assayed using the same protocol as Supplementary Table 2 , except that the plates were dispensed using a Multidrop (Thermo Scientific).
Analytical QC of compounds. The entire MLSMR library was subjected to purity analysis before plating (Discovery Partners International/Infinity Pharmaceutical). Active compounds that were obtained from commercial sources were reanalyzed for purity. For these resupplied compounds the purity analysis was performed via liquid chromatography-mass spectrometry (LC-MS) analysis on a Waters ACQUITY reversed-phase UPLC System and 1.7 µm bridged ethyl hybrid column (2.1 × 50 mm) using a linear gradient in 0.1% aqueous formic acid (5% acetonitrile in water increasing to 95% over 3 min). Compound purity was measured based upon peak integration from both UV/visible absorbance and evaporative light scattering detector readings, and compound identity was based upon mass analysis; all compounds passed purity criteria (>95%).
Processing of data to identify CYP selective fragments. The data were presented in a flat file format, where each record contained the tested substance and associated biological data. Where possible, the compound structure was recorded in SMILES format 45 -records without this information, representing samples of unknown molecular composition such as 'corn oil' , were eliminated from further consideration. Compound structures were placed in a canonical form with respect to charge/tautomer representation and protonation state. Common salts and counterions were stripped from the compounds, the protonation states were adjusted to those predicted at physiological pH using a substructure identification method (SciTegic 2006, Pipeline Pilot) and canonical tautomerization rules were applied (SciTegic 2006, Pipeline Pilot). At this point, records with identical structures, representing the same compound obtained from multiple sources, were merged. A set of simple organic functional groups were encoded as SMARTS strings (Daylight Theory Manual, Daylight Chemical Information Systems, http://www.daylight.com/dayhtml/ doc/theory/theory.smarts.html; cited 7/23/08) and used to search the set of test compounds. Where the same compound had been tested more than once on the same isoform the data were considered to be consistent if the same activity class was assigned in all cases, and, where applicable, the range of AC 50 values did not exceed one log unit. In such cases, the average logAC 50 was used as a representative value. Inconsistent data, as judged by these criteria, were discarded. The resulting data set contained 16,495 unique compounds. Of these, 16,144 were single-component structures, as determined by the absence of a period in the SMILES representation, containing only commonly occurring organic elements (H, C, N, O, P, S, Se, F, Cl, Br, I).
Self-organizing maps. Compound structures were converted into Daylight 2D fingerprints (Daylight Chemical Information Software, Daylight Chemical Information Systems), where each structure is encoded by 2,048 bits. Compounds were then clustered using the Self-Organizing Map (SOM) algorithm 46 , with the software package downloaded from http://www.cis.hut.fi/ projects/somtoolbox/, based on the similarity of their fingerprints (measured by the Euclidian distance) where each hexagon represents a cluster of structurally similar compounds, and compounds in neighboring hexagons (clusters) also share structural similarity. The hexagons in each SOM are colored by the enrichment level of active compounds (category 1 and 2) in each cluster with respect to a CYP. Briefly, for each CYP, the fraction of active compounds in each cluster (structural class) was calculated and compared to the library average fraction of active compounds, and a statistical significance (P-value from a Fisher's exact test where the null distribution is hypergeometric) calculated, where a smaller P-value indicates a higher significance level. The SOM is colored by whether the cluster is enriched or deficient in active compounds, such that a cluster with a dark red color is significantly (P << 0.05) enriched, a cluster with a dark blue color is significantly (P << 0.05) deficient in active compounds when compared to the library average, and a green cluster either has no active compounds or its fraction of active compounds is not different from the library average.
Comparisons of CYP activity to conventional and C max values.
For comparison of the bioluminescent CYP data to conventional methods, the data were taken from refs. 22, 47, 48, which included human-liver microsomes assayed with isoform-specific probe substrates using high-performance LC or LC-MS methods of detection. For comparison of potency values to the C max , values were taken from the FDA web site or ref. 49 . The graphs shown in Supplementary Figure 7 are highlighted as described 50 .
